Drug Trial Radar · NCT00913744
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion
Last checked: Nov 20, 2026Latest source record: Dec 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Jan 2010
Primary completion
Dec 2012
Study completion Apr 2013
Sponsor
- Lead sponsor
- ThromboGenicsIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of Ocriplasmin intravitreal injection, in subjects diagnosed with exudative AMD with focal vitreomacular adhesion. Ultimately, it is believed that intravitreal ocriplasmin may offer physicians a safe agent for pharmacologic vitreolysis and nonsurgical resolution of focal vitreomacular adhesion in AMD subjects where this adhesion may be causally associated with worse prognosis).
Conditions
- Exudative Age-Related Macular Degeneration
- Focal Vitreomacular Adhesion
Interventions
OcriplasminDrug
ocriplasmin intravitreal injection (125 µg)
Sham injectionDrug
Sham injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects With Focal Vitreomacular Adhesion (VMA) Release by Day 28Time frame: Day 28
Locations
27 sites in 6 countries. Site status is shown where the registry gives one.
Retina-Vitreous Associates Medical Group
Beverly Hills, California
Retinal Consultants Medical Group
Sacramento, California
University of Colorado Denver
Aurora, Colorado
Center for Retina and Maculla Disease
Winter Haven, Florida
Southeast Retina Center, PC
Augusta, Georgia
VitreoRetinal Surgery, PA
Minneapolis, Minnesota
Retina-Vitreous Center, PA
New Brunswick, New Jersey
Allegheny Ophthalmic & Orbital Associates, PC
Pittsburgh, Pennsylvania
Black Hills Regional Eye Institute
Rapid City, South Dakota
Southeastern Retina Associates
Kingsport, Tennessee
Retinal Consultants of Houston,
Houston, Texas
Valley Retina Institute
McAllen, Texas
U.Z. Leuven St. Rafaël Hospital
Leuven, Belgium
Rabelais Ophthalmologic Center
Lyon, France
Centre Paradis-Monticelli
Marseille, France
Centre Ophtalmologique d'Imagerie et de Laser
Paris, France
Centre Ophtalmologique de L'Odeon
Paris, France
Universität Bonn Augenklinik
Bonn, Germany
Universität Lübeck Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Klinik für Augenheilkunde, Universitätsklinikum Gießen, Standort Marburg
Marburg, Germany
Augenklinik der Ludwig Maximilians Universität München
München, Germany
University of Milan Department of Clinical Science "Luigi Sacco"
Milan, Italy
Largo Agostino Gemelli (University Hospital) Institute of Ophthalmology
Rome, Italy
Royal Liverpool & Broadgreen Hospital
Liverpool, United Kingdom
Moorfields Eye Hospital
London, United Kingdom
Wolverhampton Eye Infirmary New Cross Hospital
Wolverhampton, United Kingdom
Frimley Park Hospital
Frimley, Camberley, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.